HK1185875A1 - Novel gpr 119 agonists gpr119 - Google Patents
Novel gpr 119 agonists gpr119Info
- Publication number
- HK1185875A1 HK1185875A1 HK13113263.8A HK13113263A HK1185875A1 HK 1185875 A1 HK1185875 A1 HK 1185875A1 HK 13113263 A HK13113263 A HK 13113263A HK 1185875 A1 HK1185875 A1 HK 1185875A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- gpr119
- agonists
- gpr
- novel
- novel gpr
- Prior art date
Links
- 229940100607 GPR119 agonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN2803MU2010 | 2010-10-08 | ||
| PCT/IN2011/000694 WO2012046249A1 (en) | 2010-10-08 | 2011-10-05 | Novel gpr 119 agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1185875A1 true HK1185875A1 (en) | 2014-02-28 |
Family
ID=45464048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK13113263.8A HK1185875A1 (en) | 2010-10-08 | 2013-11-27 | Novel gpr 119 agonists gpr119 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8785463B2 (xx) |
| EP (1) | EP2625177B1 (xx) |
| JP (1) | JP5814377B2 (xx) |
| KR (1) | KR101563793B1 (xx) |
| AP (1) | AP2013006812A0 (xx) |
| AR (1) | AR083377A1 (xx) |
| AU (1) | AU2011311183B2 (xx) |
| BR (1) | BR112013007904A2 (xx) |
| DK (1) | DK2625177T3 (xx) |
| EA (1) | EA022501B1 (xx) |
| ES (1) | ES2551183T3 (xx) |
| HK (1) | HK1185875A1 (xx) |
| MX (1) | MX2013003736A (xx) |
| NZ (1) | NZ608708A (xx) |
| PL (1) | PL2625177T3 (xx) |
| SG (1) | SG188547A1 (xx) |
| WO (1) | WO2012046249A1 (xx) |
| ZA (1) | ZA201302249B (xx) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA031618B1 (ru) | 2011-06-09 | 2019-01-31 | Ризен Фармасьютикалз Са | Соединения-модуляторы gpr-119 |
| EP2872127A1 (en) | 2012-07-11 | 2015-05-20 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| JP2023526625A (ja) | 2020-05-19 | 2023-06-22 | キャリーオペ，インク． | Ａｍｐｋアクチベーター |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221660B1 (en) | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
| US8207147B2 (en) | 2003-12-24 | 2012-06-26 | Prosidion Limited | Heterocyclic derivatives as GPCR receptor agonists |
| GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
| MY148521A (en) * | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| NZ564759A (en) | 2005-06-30 | 2011-08-26 | Prosidion Ltd | GPCR agonists |
| EP1907384A2 (en) | 2005-06-30 | 2008-04-09 | Prosidion Limited | Gpcr agonists |
| AU2006264651A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | G-protein coupled receptor agonists |
| US20090149508A1 (en) | 2005-07-27 | 2009-06-11 | Sandoz Ag | Process for the preparation of substituted phenyl ether compounds |
| CN101263135A (zh) * | 2005-09-16 | 2008-09-10 | 艾尼纳制药公司 | 代谢调节剂和代谢相关病症的治疗 |
| US20090221639A1 (en) | 2006-04-06 | 2009-09-03 | Lisa Sarah Bertram | Heterocyclic GPCR Agonists |
| GB0607196D0 (en) | 2006-04-11 | 2006-05-17 | Prosidion Ltd | G-protein coupled receptor agonists |
| AU2007334519A1 (en) | 2006-12-14 | 2008-06-26 | Merck Sharp & Dohme Corp. | Acyl bipiperidinyl compounds, compositions containing such compounds and methods of treatment |
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| AU2008276057B2 (en) | 2007-07-17 | 2013-01-31 | Bristol-Myers Squibb Company | Method for modulating GPR119 G protein-coupled receptor and selected compounds |
| WO2009046416A1 (en) * | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
| WO2009051119A1 (ja) | 2007-10-16 | 2009-04-23 | Daiichi Sankyo Company, Limited | ピリミジルインドリン化合物 |
| WO2009106561A1 (en) | 2008-02-27 | 2009-09-03 | Biovitrum Ab (Publ) | Pyrazine compounds for treating gpr119 related disorders |
| US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
| WO2009150144A1 (en) | 2008-06-10 | 2009-12-17 | Inovacia Ab | New gpr119modulators |
| KR101345941B1 (ko) | 2008-07-11 | 2013-12-30 | 아이알엠 엘엘씨 | Ｇｐｒ119 활성의 조절제로서의 4-페녹시메틸피페리딘 |
| TW201006821A (en) | 2008-07-16 | 2010-02-16 | Bristol Myers Squibb Co | Pyridone and pyridazone analogues as GPR119 modulators |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| WO2010075271A1 (en) * | 2008-12-23 | 2010-07-01 | Schering Corporation | Bicyclic heterocycle derivatives and methods of use thereof |
| EP2379542B1 (en) | 2008-12-24 | 2013-02-13 | Cadila Healthcare Limited | Novel oxime derivatives |
-
2011
- 2011-10-05 US US13/824,552 patent/US8785463B2/en not_active Expired - Fee Related
- 2011-10-05 DK DK11805633.2T patent/DK2625177T3/en active
- 2011-10-05 EP EP11805633.2A patent/EP2625177B1/en active Active
- 2011-10-05 JP JP2013532319A patent/JP5814377B2/ja not_active Expired - Fee Related
- 2011-10-05 BR BR112013007904A patent/BR112013007904A2/pt not_active IP Right Cessation
- 2011-10-05 PL PL11805633T patent/PL2625177T3/pl unknown
- 2011-10-05 KR KR1020137008931A patent/KR101563793B1/ko not_active IP Right Cessation
- 2011-10-05 ES ES11805633.2T patent/ES2551183T3/es active Active
- 2011-10-05 SG SG2013019062A patent/SG188547A1/en unknown
- 2011-10-05 WO PCT/IN2011/000694 patent/WO2012046249A1/en active Application Filing
- 2011-10-05 EA EA201390488A patent/EA022501B1/ru not_active IP Right Cessation
- 2011-10-05 MX MX2013003736A patent/MX2013003736A/es active IP Right Grant
- 2011-10-05 NZ NZ608708A patent/NZ608708A/en not_active IP Right Cessation
- 2011-10-05 AP AP2013006812A patent/AP2013006812A0/xx unknown
- 2011-10-05 AU AU2011311183A patent/AU2011311183B2/en not_active Ceased
- 2011-10-11 AR ARP110103746A patent/AR083377A1/es unknown
-
2013
- 2013-03-26 ZA ZA2013/02249A patent/ZA201302249B/en unknown
- 2013-11-27 HK HK13113263.8A patent/HK1185875A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013538870A (ja) | 2013-10-17 |
| AR083377A1 (es) | 2013-02-21 |
| AU2011311183A1 (en) | 2013-04-04 |
| WO2012046249A1 (en) | 2012-04-12 |
| BR112013007904A2 (pt) | 2019-09-24 |
| US8785463B2 (en) | 2014-07-22 |
| MX2013003736A (es) | 2013-05-09 |
| EA022501B1 (ru) | 2016-01-29 |
| JP5814377B2 (ja) | 2015-11-17 |
| EP2625177B1 (en) | 2015-07-29 |
| PL2625177T3 (pl) | 2015-12-31 |
| DK2625177T3 (en) | 2015-10-12 |
| KR101563793B1 (ko) | 2015-10-27 |
| EP2625177A1 (en) | 2013-08-14 |
| AP2013006812A0 (en) | 2013-04-30 |
| KR20130064801A (ko) | 2013-06-18 |
| US20130252980A1 (en) | 2013-09-26 |
| EA201390488A1 (ru) | 2013-08-30 |
| AU2011311183B2 (en) | 2014-09-25 |
| NZ608708A (en) | 2015-05-29 |
| ES2551183T3 (es) | 2015-11-16 |
| SG188547A1 (en) | 2013-04-30 |
| ZA201302249B (en) | 2013-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201002983D0 (en) | Nutritinal composition | |
| PL2550243T3 (pl) | Kompozycja ogniotrwała | |
| ZA201200063B (en) | Novel gpr 119 agonists | |
| GB201006178D0 (en) | Composition | |
| ZA201206841B (en) | Novel composition | |
| HK1185875A1 (en) | Novel gpr 119 agonists gpr119 | |
| GB201005927D0 (en) | Improved composition | |
| GB201004717D0 (en) | Composition | |
| GB201006175D0 (en) | Composition | |
| GB201006182D0 (en) | Composition | |
| GB201006012D0 (en) | Composition | |
| GB201002356D0 (en) | Composition | |
| GB201019720D0 (en) | Corcost- T 1 T | |
| GB201016999D0 (en) | Novel composition | |
| GB201009366D0 (en) | Ts 33 | |
| GB201008537D0 (en) | Ts 25 | |
| GB201008248D0 (en) | Ts 23 | |
| GB201007391D0 (en) | Ts 18 | |
| GB201007393D0 (en) | Ts 17 | |
| GB201002265D0 (en) | Ts 16 | |
| GB201002028D0 (en) | Ts 15 | |
| GB201002063D0 (en) | Ts 14 | |
| GB201001986D0 (en) | Ts 13 | |
| GB201001771D0 (en) | Ts 10 | |
| GB201001767D0 (en) | Ts 9 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20191008 |